BioLargo — Guidance: Odor-No-More break-even by YE19

BioLargo (US: BLGO)

Last close As at 21/11/2024

0.27

0.00 (0.00%)

Market capitalisation

70m

More on this equity

Research: Healthcare

BioLargo — Guidance: Odor-No-More break-even by YE19

BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially available in late 2019 or early 2020 and eventually operating independently.

Analyst avatar placeholder

Written by

Healthcare

BioLargo

Guidance: Odor-No-More break-even by YE19

Healthcare & industrial services

Spotlight – QuickView

4 April 2019

Price

$0.18

Market cap

$26m

Share price graph

Share details

Code

BLGO

Listing

OTCQB

Shares in issue

143.1m

Net debt ($m) at 31 December 2018

2.8

Business description

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Bull

Diversified portfolio of products.

Unique technology with broad applications.

CupriDyne gaining market share.

Bear

Additional capital needed.

Sales ramp has been slow.

Regulatory and development risk for Clyra and AOS.

Analyst

Nathaniel Calloway

+1 646 653 7036

BioLargo is a research client of Edison Investment Research Limited

BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially available in late 2019 or early 2020 and eventually operating independently.

Margins improving for Odor-No-More

Odor-No-More continues to be loss-making (gross margin of $552,000 and net loss of $433,000 for 2018), although the investment in increased sales staff is showing early signs that this is translating into an improved bottom line, and in Q418, the unit’s operational loss was reduced to $51,000. CupriDyne Clean was recently integrated into the purchasing system for its fourth national account, and BioLargo has guided to break-even by the end of 2019. The company has also announced a strategic initiative to target the product to the cannabis industry, and has established an undisclosed distributer agreement in the space.

Clyra animal data due with FDA in six months

In December 2018, Clyra completed its transaction with Scion Solutions for intellectual property to its SkinDisc stem cell therapy technology. Clyra is independently financed and the goal is to acquire a portfolio of wound care products and to operate as an independent company around the end of 2019. The FDA has provided guidance on the market clearance pathway for the company’s iodine based antimicrobial product. The company is preparing to initiate a large animal study to support a 510(k) application, and it expects to be able to provide the needed information to the FDA within six months.

AOS enters additional pilot projects

The AOS product developed by BioLargo Water is currently being deployed in a number of pilot projects and is largely financed via grants. The first pilots are being placed in a poultry processing facility in Alberta and a microbrewery in California. Additionally the company is negotiating a pilot program for the processing of storm water in California in accordance with a recent initiative to provide $300m for this purpose in Los Angeles. These projects have shifted resources away from the petrochemical waste water pilot in Tianjin, where funding has not been secured. Per guidance, AOS is targeting commercialization in late 2019 or early 2020.

Historical financials

Year
end

Revenue
($m)

PBT
($m)

EPS
($)

DPS
($)

P/E
(x)

Yield
(%)

12/15

0.1

(5.1)

(0.06)

0.0

N/A

N/A

12/16

0.3

(8.1)

(0.09)

0.0

N/A

N/A

12/17

0.5

(9.5)

(0.10)

0.0

N/A

N/A

12/18

1.4

(10.7)

(0.09)

0.0

N/A

N/A

Source: BioLargo reports

General disclaimer and copyright

This report has been commissioned by BioLargo and prepared and issued by Edison, in consideration of a fee payable by BioLargo. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2019 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited (“FTSE”) © FTSE 2019. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

The Investment Research is a publication distributed in the United States by Edison Investment Research, Inc. Edison Investment Research, Inc. is registered as an investment adviser with the Securities and Exchange Commission. Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1,185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on BioLargo

View All

Healthcare

BioLargo — Firing on all cylinders

Healthcare

BioLargo — Clyra launches Clyraguard

Healthcare

BioLargo — A record-setting year

Latest from the Healthcare sector

View All Healthcare content

Research: Energy & Resources

Hurricane Energy — Focus shifting to drilling ahead of EPS first oil

With the Aoka Mizu FPSO now on station and hooked up at the Lancaster field, early production system (EPS) first oil remains on track for the end of H119. Hurricane (HUR) is currently focusing on topside commissioning prior to start up, which will be followed by a ramp-up period to a targeted gross plateau rate of 20kbd. In addition to progressing Lancaster, the company has a full programme of activity in its neighbouring Greater Warwick Area (GWA), with a three-well E&A programme expected to kick off in Q219 at Warwick Deep. This accelerated GWA programme is being made possible by Hurricane’s 2018 farm-out to Spirit Energy. Our risked valuation stands at 102.3p/share (from 102.8p/share) as we remove Edison’s 5% capex cost contingency, roll forward NAV and adjust our short-term oil price assumptions (long-term Brent remains $70/bbl).

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free